Drug name
Last update: Jul 2025cabotegravir PH20
Developer(s)
Drug information
Not provided
long-acting cabotegravir coadministered with recombinant human hyaluronidase PH20 (rHuPH20)
Not provided
Small molecule
integrase strand transfer inhibitor (INSTI)
Not provided
Unknown
Unknown
Therapeutic area(s)
- HIV
- Pre-Exposure Prophylaxis (PrEP)
- Treatment
- Prevention
Administration route
Subcutaneous, Intramuscular, To be determined
Associated long-acting platforms
Aqueous drug particle suspension
Use of drug
- Administered by a community health worker
- Administered by a nurse
- To be determined
Not provided
Not provided
Dosage
Not provided
Not provided
Not provided
Not provided
Not provided
Associated technologies
Not provided
Comment & Information
Developer(s)
ViiV Healthcare
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients
Not provided
Not provided
Not provided
Delivery device(s)
Not provided
Combination dosing regimen of cabotegravir and PH20 hyaluronidase
The inventions herein relate to combination dosing regimen comprising administering cabotegravir and hyaluronidase. Provided are dosing regimens and combinations for treating or preventing Human Immunodeficiency Virus (HIV) infection.
US20230405095
Combination
VIIV HEALTHCARE UK NO 7 LTD; HALOZYME INC
Not provided
June 12, 2043
Pending (US only)
Publications
There are no publication
Additional documents
No documents were uploaded
Useful links
There are no additional links
Collaborate for development
Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology
Share technical information for match-making assessment
Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit
Work with MPP to expand access in LMICs
In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing